Home | Find A Doctor | Contact Us

 

ECOG2809:Androgen Receptor Modulation: Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy


Principal Investigator: Ilan Shapira, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
Bicalutamide (a type of hormonal therapy) is approved by the FDA (Food and Drug Administration) for use in prostate cancer and MK-2206 is an investigational agent that has not been approved by the FDA for use in prostate cancer. The purpose of this study is to compare the effects, good and/or bad, of MK-2206 and Bicalutamide, versus Bicalutamide alone on lowering your prostate specific antigen (PSA). In this study, you will receive either MK-2206 combined with Bicalutamide OR Bicalutamide alone. If you are selected to receive Bicalutamide alone, you will not be eligible to receive MK-2206 as part of this study. The study will also evaluate the safety of the Bicalutamide and MK-2206 combination therapy. It is thought that the combination of drugs used in this studymay slow or stop the rising of your PSA and prevent your cancer from coming back or keep it in remission for a longer period of time. 


Eligibility and Treatment Plan:

  • Male of at least 18 years old
  • No HIV-positive patients
  • Not eligible with some impaired cardiac function

Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System